Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_3
1
25%
Ph phase_2
2
50%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Active, not recruiting3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)

Trials by Status

active_not_recruiting375%
completed125%

Recent Activity

3 active trials
Showing 4 of 4
active_not_recruitingphase_3

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

NCT04164199
active_not_recruitingphase_2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT05635708
active_not_recruitingphase_1

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

NCT04649385
completedphase_2

A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT06029127

Clinical Trials (4)

Showing 4 of 4 trials
NCT04164199Phase 3

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Active Not Recruiting
NCT05635708Phase 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Active Not Recruiting
NCT04649385Phase 1

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Active Not Recruiting
NCT06029127Phase 2

A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4